Castanet Tolsan, France

Phillipe LeLong

This inventor holds 1 USPTO granted patent. Top assignee: Other. Active years: 1996.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:

goldMedal1 out of 834,350 
Other
 patents

Years Active: 1996

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Phillipe LeLong

Introduction

Phillipe LeLong is a notable inventor based in Castanet Tolsan, France. He has made significant contributions to the field of biochemistry, particularly through his innovative work on enzymes. His research focuses on the fragmentation of N-acetylheparosan, which has important implications in various scientific applications.

Latest Patents

LeLong holds a patent for an enzyme intended for the fragmentation of N-acetylheparosan. This invention relates to an enzyme capable of fragmenting a high molecular mass N-acetylheparosan. The enzyme was obtained using the strain Escherichia coli (K5), strain SEBR 3282. This patent showcases his expertise in enzymatic processes and their potential uses in biotechnology.

Career Highlights

Throughout his career, Phillipe LeLong has demonstrated a commitment to advancing scientific knowledge. His work has not only contributed to the understanding of enzymatic functions but also opened new avenues for research in related fields. His innovative approach has positioned him as a valuable contributor to the scientific community.

Collaborations

LeLong has collaborated with notable colleagues, including Guy Etienne Tenaille d'Estais and Marc Louis Salome. These partnerships have enriched his research and expanded the impact of his inventions.

Conclusion

Phillipe LeLong's contributions to the field of biochemistry, particularly through his patented enzyme, highlight his innovative spirit and dedication to scientific advancement. His work continues to inspire future research and development in enzymatic applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…